Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on August 16, 2018. The report covers a specific corporate event occurring on the same date regarding the company's clinical trial progress.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a clinical development milestone rather than financial performance.
Material Changes
The material event reported is the completion of the second dosing cohort for Onvansertib, a first-in-class, 3rd generation, highly-selective oral Polo-like Kinase 1 (PLK1) Inhibitor. This milestone occurred in a Phase 1b/2 clinical trial for patients with Acute Myeloid Leukemia (AML), where the drug was administered in combination with standard-of-care low-dose cytarabine (LDAC).
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the inherent nature of clinical trials. The document serves to disclose the completion of a trial phase as an "Other Event" under Item 8.01.
Investor Verification Checklist
- Verify the registrant name is Trovagene, Inc., not Cardiff Oncology, Inc.
- Confirm the details of the Onvansertib Phase 1b/2 trial results in the attached press release (Exhibit 99.1).
- Review subsequent filings for safety data or efficacy results following the completion of the second dosing cohort.
- Check the company's cash runway and burn rate in the most recent 10-Q or 10-K, as this 8-K contains no financial data.